SCYNEXIS (SCYX) Short-Term Debt to Capital

SCYNEXIS Inc - graphic logo of issuer SCYX

SCYNEXIS, Inc. (SCYX) minimizes commercial threats through global collaboration with industry behemoths and the development of universal antimycotics. This price action shown below underscores the status of the company as a creator of a unique class of drugs, providing a market advantage in the fight against resistant pathogens; meanwhile, the indicator stands at 0.01. Regarding the environmental aspect, the firm maintains a conservative approach by outsourcing drug production.

scynexis.com (SCYX) Ratio of Short-Term Indebtedness to Capital: for the period 07/04/2022 - 10/28/2026

Metric breakdowns and analytics for Scynexis (SCYX)

- price and consensus price forecast:
Stock Price SCYNEXIS, Inc.|SCYX - Fair Value Consensus
- market capitalization data:
Market Capitalization SCYNEXIS Inc|SCYX - Enterprise Value
- book capitalization data:
Net Assets per Single Share SCYNEXIS|SCYX - Accounting Value of Company|Market Value to Book Value Ratio scynexis.com|SCYX - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital SCYNEXIS, Inc.|SCYX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio SCYNEXIS, Inc.|SCYX - Aggregate Debt Obligations|Debts to Book Capitalization SCYNEXIS Inc|SCYX - Long-Term Debt Volume|Company Short-Term Debt SCYNEXIS
Comprehensive company analysis:SCYNEXIS, SCYX
Brand item of scynexis.com

Investors must evaluate the stability of the financial architecture of SCYNEXIS, Inc. (SCYX), as the commercialization of new antifungal agents requires significant resources and reliable funding. By analyzing the short-term debt to equity trend, one can determine the balance between short-term liabilities and equity, revealing either liquidity risks or an underutilization of leverage to accelerate expansion within the pharmaceutical market.

Competing companies

Summit Therapeutics Inc (SMMT) - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Moderna Therapeutics (MRNA)|Short-Term Debt to Capital PCVX (Vaxcyte, Inc.)|tarsusrx.com - Short-Term Debt to Capital|Short-Term Debt to Equity CorMedix (CRMD)|MCRB: Ratio of Short-Term Indebtedness to Capital|SPRO (Spero) - Short-Term Debt to Equity|AN2 Therapeutics (ANTX) - Short-Term Debt to Equity Ratio|PYPD (PolyPid Ltd) - Short-Term Debt to Capital|Short-Term Debt to Capital ysbiopharm.com (LSB)|Iterum Therapeutics plc (ITRM) - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital biomx.com (PHGE)|Short-Term Debt to Capital SNGX|60 Degrees Pharmaceuticals Inc. - Short-Term Debt to Capital Coefficient|Oragenics, Inc. (OGEN) - Short-Term Debt to Equity|ONCO - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital OpGen (OPGN)